This site is intended for Healthcare Professionals outside the US

MF
PV
  1. Efficacy
  2. Spleen Reduction

Rapid, durable, and significant reductions in splenomegaly with JAKAVI, regardless of JAK2V617F mutation status1

Significant reduction in spleen volume throughout the 48-week study period and 5-year follow-up1,2

COMFORT-II: Percentage of patients who achieved ≥35% reduction in spleen volume at Week 481

Significant reduction in spleen volume was seen with JAK inhibitor therapy - JAKAVI

Adapted from: Harrison C et al. N Engl J Med. 2012;366:787-798.1
  • 53.4% of patients treated with JAKAVI (78/146) achieved ≥35% reduction in spleen volume at any time during the 5-year follow-up3

Significant reduction in splenomegaly regardless of JAK2V617F mutation status1,4

Percentage change in spleen volume, by JAK2V617F mutation, from baseline at Week 484

Patients treated with JAKAVI, a JAK2 Inhibitor, experienced significant spleen volume reduction regardless of mutation status

Adapted from: Harrison C, Kiladjian J-J, Barosi G; for the COMFORT-II authors. Ruxolitinib for myelofibrosis [letter]. N Engl J Med. 2012;366(21):2032-2034.3
Based on a post hoc analysis.
  • 97% of patients treated with JAKAVI (132/136) achieved any reduction in spleen volume at any time during the 48-week study period, while a majority of patients in the BAT arm progressively worsened1*

Significant spleen reductions sustained at 3-year follow-up2

COMFORT-II: Rapid and durable reduction in spleen volume with JAKAVI2

Rapid and durable reduction in spleen volume in Myelofibrosis patients with JAKAVI, a JAK2 Inhibitor

Adapted from: Cervantes F et al. Blood. 2013;122:4047-4053.2
Based on a prespecified exploratory endpoint. JAKAVI included both randomised and extension phases; BAT included randomised phase only and did not include assessments after crossover.
  • Median time to ≥35% reduction in spleen volume was as early as 12 weeks1
  • Kaplan-Meier estimated probabilities of maintaining a ≥35% reduction in spleen volume at Weeks 48 and 144 were 73% (95% CI: 61-82) and 50% (95% CI: 36-63), respectively2

JAKAVI Treatment in Clinical Practice: Treating splenomegaly in a patient with high disease burden but low IPSS risk

The IPSS is an effective tool to predict survival time; however, it may not account for the impact of MF-related symptoms, including splenomegaly. Watch the video below to learn more from Dr Claire Harrison on treating splenomegaly in patients with MF.

 

Next: Significant symptom improvement with JAKAVI

BAT=best available therapy; COMFORT=Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment; IPSS= International Prognostic Scoring System; MF=myelofibrosis.

*Based on a prespecified exploratory endpoint.

References:

  1. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
  2. Cervantes F, Vannucchi AM, Kiladjian J-J, et al; for the COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.
  3. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Onc. 2017;10(1):156.
  4. Harrison C, Kiladjian J-J, Barosi G; for the COMFORT-II authors. Ruxolitinib for myelofibrosis [letter]. N Engl J Med. 2012;366(21):2032-2034.